CALIFORNIA | LOCAL
March 17, 1993
I would like to respond to the protest at Amgen by members of ACT/UP L.A. I believe the protesters should know how much Amgen has done for the community. In recent months, Amgen has shown its concern for the service organization, AIDS Care, by allowing boxes for the collection of food by employees in their company. This food was then turned over to be used by clients of AIDS Care through the Daily Provisions Program. In an ironic twist, the same day ACT/UP protested at Amgen, AIDS Care received a grant check from Amgen for several thousand dollars to help its clients purchase prescription medication.
March 7, 2008 |
Amgen Inc. will pay Kyowa Hakko Kogyo Co. $100 million initially and as much as $420 million tied to the development of an experimental medicine for inflammation and cancer, the companies said. Kyowa Hakko is the Tokyo-based drug unit of Kirin Holdings Co. The deal gives Thousand Oaks-based Amgen a potential medication that could join its anti-inflammatory medicine Enbrel. Shares fell $1.01 to $44.24.
February 6, 2008 |
Amgen Inc. must defend a lawsuit over claims that it misled investors about safety issue with its top-selling anemia drugs, Epogen and Aranesp. A U.S. district judge in Los Angeles denied Amgen's request to dismiss a consolidated shareholders' complaint. Shareholders say Thousand Oaks-based Amgen artificially inflated its stock price from April 2004 to May 2007 by making false statements about the drugs' safety and by marketing them for uses not approved by the Food and Drug Administration.
July 15, 2008 |
Amgen Inc. said its experimental osteoporosis drug denosumab strengthened bones and reduced spinal fractures in men undergoing treatment for prostate cancer in a clinical trial. In the three-year study, 1,400 men taking denosumab had improved bone density and half as many spinal fractures compared with a placebo, the Thousand Oaks company said.
April 25, 2012 |
Biotech giant Amgen Inc. reported a 5% increase in first-quarter profit, lifted by solid sales overall that helped offset continued weakness for its anemia treatments. The Thousand Oaks company reported profit of $1.18 billion, or $1.48 a share, for the three months ended March 31, compared with net income of $1.13 billion, or $1.20 a share, a year earlier. Revenue for the quarter grew 9% to $4.05 billion. The results topped analysts' expectations for earnings per share of $1.46, excluding one-time items, and sales of $3.94 billion.
January 27, 2012 |
Biotech giant Amgen, fresh off mixed earnings, said it will shell out $1.16 billion to broaden its product pipeline by buying fellow drug developer Micromet Inc. Thousand Oaks-based Amgen is already one of the world's premier pharmaceutical firms, but it's saddled with mostly older products, such as anemia treatment Epogen and arthritis medication Enbrel. Its portfolio is facing more competition and high expenses as similar products hit the market, analysts said. Amgen's profit in 2011 fell 20.4% year over year - largely because of higher costs - to about $3.7 billion, or $4.07 a share, the company said after the markets closed Thursday.